S&P 500 falls on pressure from retail stocks, weak jobless claims
Scott Moomaw, the Chief Commercial Officer of Liquidia Corp (NASDAQ:LQDA), recently sold 592 shares of the company’s common stock. The transaction, executed on March 3, 2025, was conducted at a price of $15.45 per share, bringing the total value of the sale to $9,146. This sale was made under a pre-established Rule 10b5-1 trading plan, which Moomaw adopted on June 13, 2022. The stock has shown remarkable momentum, gaining over 66% in the past six months, with the company now valued at $1.28 billion.
In addition to the sale, Moomaw acquired 1,875 shares of common stock on February 28, 2025, through the exercise of restricted stock units (RSUs). These RSUs were part of a grant awarded on January 16, 2022, with a vesting schedule that began on February 28, 2023. The recent acquisition of shares did not involve any cash transaction, as the RSUs were converted into common stock at no cost. According to InvestingPro analysis, the company maintains strong liquidity with a current ratio of 6.33, indicating robust short-term financial health.
Following these transactions, Moomaw’s direct ownership stands at 218,150 shares. The sale of shares was primarily executed to cover taxes associated with the RSU settlement. Liquidia Corp, headquartered in Morrisville, North Carolina, continues to be a player in the pharmaceutical preparations industry. The company is approaching its next earnings announcement on March 13, 2025, with analysts maintaining a strong buy consensus.
In other recent news, Liquidia Corporation faced a legal challenge when the U.S. District Court for the District of Columbia ruled against the company regarding its lawsuit against the U.S. Food and Drug Administration (FDA). The lawsuit was centered on the FDA’s decision to grant a three-year regulatory exclusivity to Tyvaso DPI, a product of United Therapeutics (NASDAQ:UTHR) Corporation. The court denied Liquidia’s motion for summary judgment while granting summary judgment motions filed by the FDA and United Therapeutics. This decision means that the exclusivity for Tyvaso DPI will remain in place until May 23, 2025. Additionally, United Therapeutics filed a cross claim challenging the FDA’s acceptance of Liquidia’s amended New Drug Application (NDA) for review. Liquidia and the FDA have both submitted motions to dismiss this cross claim, but the court has not yet made a decision on these motions. These developments are significant as they impact Liquidia’s competitive position in the market. The information is based on legal proceedings and filings, as detailed in SEC documentation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.